ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients
Authors
Keywords
-
Journal
Journal of Innate Immunity
Volume -, Issue -, Pages 1-11
Publisher
S. Karger AG
Online
2021-12-02
DOI
10.1159/000519090
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?
- (2020) Serena Colafrancesco et al. AUTOIMMUNITY REVIEWS
- Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
- (2020) Evangelos J. Giamarellos-Bourboulis et al. Cell Host & Microbe
- Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis
- (2020) George Dimopoulos et al. Cell Host & Microbe
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
- (2020) Chuan Qin et al. CLINICAL INFECTIOUS DISEASES
- Characterization of the Inflammatory Response to Severe COVID-19 Illness
- (2020) Oliver J McElvaney et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases
- (2020) Kai Kappert et al. BIOMARKERS
- A minimal common outcome measure set for COVID-19 clinical research
- (2020) John C Marshall et al. LANCET INFECTIOUS DISEASES
- Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19
- (2020) Raphaël Cauchois et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID‐19: A Case Series
- (2020) Iris Navarro‐Millán et al. Arthritis & Rheumatology
- Soluble Urokinase Receptor (SuPAR) in COVID-19–Related AKI
- (2020) Tariq U. Azam et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
- (2020) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
- (2020) Olivier Hermine et al. JAMA Internal Medicine
- Effects of Tocilizumab in COVID-19 patients: a cohort study
- (2020) Christine A. Vu et al. BMC INFECTIOUS DISEASES
- The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome
- (2020) Mathieu Blot et al. Journal of Translational Medicine
- Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
- (2020) Carlos Salama et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
- (2020) Giorgio Bozzi et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome
- (2016) Bita Shakoory et al. CRITICAL CARE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now